XML 79 R66.htm IDEA: XBRL DOCUMENT
v3.26.1

License Agreements - Vaccine Products License (Details) |  | 12 Months Ended
--- | --- | ---
Apr. 10, 2020 USD ($) Milestone | Dec. 31, 2025 USD ($)
License Agreements |  |
Forgiveness of unrelated vendor payables |  | $ 2,142,297
Vaccine license and development agreement with TDT | Vaccine Products and Vaccine Diagnostics |  |
License Agreements |  |
Upfront payment of license agreement fees | $ 4,000,000 |
Annual maintenance fees | $ 400,000 |
Maintenance fee |  | 0
Unpaid annual maintenance fees, short term debt interest rate (%) | 1.50% |
Number of developmental and regulatory milestone payments for first product development | Milestone | 4 |
Maximum aggregate milestone commitment fund for first product development | $ 12,000,000 |
Number of developmental and regulatory milestone payments for each additional product development | Milestone | 4 |
Maximum milestone commitment fund for each additional product development | $ 6,000,000 |
Vaccine license and development agreement with TDT | Vaccine Products and Vaccine Diagnostics | Net sales of period from first commercial sale until patent expires | Minimum |  |
License Agreements |  |
Percentage of royalty fees (%) | 10.00% |
Vaccine license and development agreement with TDT | Vaccine Products and Vaccine Diagnostics | Net sales of period from first commercial sale until patent expires | Maximum |  |
License Agreements |  |
Percentage of royalty fees (%) | 15.00% |
Vaccine license and development agreement with TDT | Vaccine Products and Vaccine Diagnostics | 10 years from first commercial sale of products |  |
License Agreements |  |
Number of years from first commercial sale of products (in years) | 10 years |
Vaccine license and development agreement with TDT | Vaccine Products and Vaccine Diagnostics | 10 years from first commercial sale of products | Minimum |  |
License Agreements |  |
Percentage of royalty fees (%) | 5.00% |
Vaccine license and development agreement with TDT | Vaccine Products and Vaccine Diagnostics | 10 years from first commercial sale of products | Maximum |  |
License Agreements |  |
Percentage of royalty fees (%) | 9.00% |
CAR-T License and Vaccine License with TDT |  |
License Agreements |  |
Forgiveness of unrelated vendor payables |  | $ 2,142,297

X
- Definition Amount of forgiveness of unrelated vendor payable. + References No definition available. + Details
Name: | limn_ForgivenessOfUnrelatedVendorPayable
Namespace Prefix: | limn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of license agreement incurred in maintenance fees. + References No definition available. + Details
Name: | limn_LicenseAgreementMaintenanceFees
Namespace Prefix: | limn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of maximum aggregate milestone commitment fund for first product development. + References No definition available. + Details
Name: | limn_LicenseMaximumAggregateMilestoneCommitmentsFundForFirstProductDevelopment
Namespace Prefix: | limn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of maximum milestone commitment fund for each additional product development. + References No definition available. + Details
Name: | limn_LicenseMaximumMilestoneCommitmentFundForEachAdditionalProductDevelopment
Namespace Prefix: | limn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Number of milestone developmental and regulatory milestone payments for each additional product development. + References No definition available. + Details
Name: | limn_NumberOfMilestonePaymentsForEachAdditionalProductDevelopment
Namespace Prefix: | limn_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of milestone developmental and regulatory milestone payments for first product development. + References No definition available. + Details
Name: | limn_NumberOfMilestonePaymentsForFirstProductDevelopment
Namespace Prefix: | limn_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of years from the first commercial sale of CAR-T product or CAR-T Diagnostic. + References No definition available. + Details
Name: | limn_RoyaltyFeesNumberOfYearsFromFirstCommercialSaleOfProducts
Namespace Prefix: | limn_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of royalty fees + References No definition available. + Details
Name: | limn_RoyaltyFeesPercentage
Namespace Prefix: | limn_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of interest rate of short-term debt being converted from the unpaid annual maintenance fees. + References No definition available. + Details
Name: | limn_UnpaidAnnualMaintenanceFeesShortTermDebtInterestRate
Namespace Prefix: | limn_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of upfront payment of license agreement fee. + References No definition available. + Details
Name: | limn_UpfrontPaymentOfLicenseAgreementFees
Namespace Prefix: | limn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Cost of maintenance incurred and directly related to good produced and service rendered. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_CostMaintenance
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=limn_VaccineProductsAndVaccineDiagnosticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=limn_CarTLicenseAndVaccineLicenseWithTdtMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |